Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-03-31
2009-11-10
Bristol, Lynn A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S155100, C435S326000, C530S388800
Reexamination Certificate
active
07615216
ABSTRACT:
Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5202238 (1993-04-01), Fell, Jr. et al.
patent: 5204244 (1993-04-01), Fell et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 6610834 (2003-08-01), Lobo
patent: 2001/0000241 (2001-04-01), Li et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2002/0146415 (2002-10-01), Olson et al.
patent: 2002/0147147 (2002-10-01), Molling et al.
patent: 2003/0003440 (2003-01-01), Lopalco
patent: 2003/0044411 (2003-03-01), Olson et al.
patent: 2003/0049251 (2003-03-01), Barbas et al.
patent: 2003/0099645 (2003-05-01), Lobo
patent: 2003/0100058 (2003-05-01), Roschke et al.
patent: 2003/0152913 (2003-08-01), Hua et al.
patent: 2003/0165988 (2003-09-01), Hua et al.
patent: 2003/0166024 (2003-09-01), Rosen et al.
patent: 2003/0166870 (2003-09-01), Wu et al.
patent: 2003/0195348 (2003-10-01), Combadiere et al.
patent: 2003/0228306 (2003-12-01), Olson et al.
patent: 2004/0043033 (2004-03-01), Green
patent: 0 307 434 (1993-09-01), None
patent: 1 207 202 (2002-05-01), None
patent: 1 161 456 (2004-12-01), None
patent: WO 87/05330 (1987-09-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/35409 (2000-06-01), None
patent: WO 01/42308 (2001-06-01), None
patent: WO 01/43779 (2001-06-01), None
patent: WO 01/58915 (2001-08-01), None
patent: WO 01/58916 (2001-08-01), None
patent: WO 02/22077 (2002-03-01), None
patent: WO 02/083172 (2002-10-01), None
patent: WO 03/033666 (2003-04-01), None
patent: WO 03/066830 (2003-08-01), None
patent: WO 03/072766 (2003-09-01), None
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Rudikoff et al (Proc Natl Acad Sci,USA 1982 vol. 79 p. 1979).
Casset et al. ((2003) BBRC 307, 198-205).
Holm et al (Molec. Immunol. (2007) 44, 1075-1084).
MacCallum et al. (J. Mol. Biol. (1996) 262, 732-745).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Vincenti, Am. J. Transpl. 2:898-903 (2002).
Shaheen et al., Curr. Opin. Infect. Dis. 17:7-16 (2004).
Choudry et al., Expert Opin. Biol. Ther. 6:523-531 (2006).
Adachi, A., et al., “Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone,”Journal of Virology59 (1986) 284-291.
Angal, S., et al., “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human IgG4 Antibody,”Molecular Immunology. 30 (1993) 105-108.
Aplin, J.D., et al., “Preparation, Properties, and Applications of Carbohydrates Conjugates of Proteins and Lipids,”CRC Crit. Rev. Biochem. 4 (1981) 259-306.
Barnes, L.M., et al., “Characterization of the Stability of Recombinant Protein Production in the GS-NS0 Expression System,”Biotech. Bioeng. 73 (2001) 261-270.
Barnes, L.M., et al., “Advances in Animal Cell Recombinant Protein Production: GS-NS0 Expression System,”Cytotechnology32 (2000) 109-123.
Brunhouse, R., et al., Isotypes of IgG: Comparison of the Primary Structures of Three Pairs of Isotypes which Differ in their Ability to Activate complement,Molecular Immunology. 16 (1979) 907-917.
Burton D.R., et al., “The C1q Receptor site on immunoglobulin G,”Nature288 (1980) 338-344.
Carter, P., et al., “Humanization of an Anti-p185HER2Anibody Human Cancer Theapy,”Proc. Natl. Acad. Sci, 89 (1992) 4285-4289.
Dean, M., et al., “Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene,”Science273 (1996) 1856-1852.
Durocher, Y., et al., “High-level and high-throughput Recombinant Protein Production by Transient Transfection of Suspension-growing human 293-EBNA1 Cells,”Nucleic Acids Research30 (2002) E9.
Edelman, G.M., et al., “The Covalent Structure of Entire—G Immunoglobin Molecule.”Natl. Acad. Sci. USA63 (1969) 78-85.
Edge, A.S., et al., “Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid,”Analytical Biochemistry118 (1981) 131-137.
Geisse, S. et al., “Eukaryotic Expression Systems: A Comparison,”Protein Expression and Purification8 (1996) 271-282.
Herareh, M., et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,”J of Virology75 (2001) 12161-12168.
Idusogie E.E., et al., “Mapping of the C1q Binding Site of Rituxan, a Chimeric Antibody with a Human IgG1 Fc,”J. Immunology164 (2000) 4178-4184.
Johnson, G., et al., “Kabat Database and its applications: 30 years after the first variability plot,”Nucleic Acids Research28 (2000) 214-218.
Kaufman, R.J., “Overview of Vector Design for Mammalian Gene Expression,”Molecular Biotechnology16 (2000) 151-160.
Lee, B. et al., “Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function,”J. of Biological Chem. 274 (1999) 9617-9626.
Lukas, T.J., et al., “Inhibition of C1-Mediated Immune Hemolysis by Monomeric and Dimeric Peptides from the Second Constant Domain of Human Immunoglobulin G1,” Journal of Immunology127 (1981) 2555-2560.
Lund, J., et al., “Oligosaccharide-protein Interations in IgG can Moldulate Recognition by Fcγ Receptors,”FASEB9 (1995) 115-119.
Makrides, S.C., “Components of Vectors for Gene Transfer and Expression in Mammalian Cells,”Protein Expression and Purification17 (1999) 183-202.
Morgan, A., et al., “The N-terminal end of the CH2 Domain of Chimeric Human IgG1 Anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII Binding,”Immunology86 (1996) 319-324.
Morrison, S.L., et al., “Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains,”Proc. Natational. Acad. Science USA81 (1984) 6851-6855.
Neuberger, M.S. et al., “A Hapten-specific Chimaeric IgE Antibody with Human Physiological Effector Function,” Nature 314 (1985) 268-270.
Norderhaug, L., et al., “Versatile Vectors for Transient and Stable Expression of Recombinant Antibody Molecules in Mammalian Cells,”Journal of Immunological Methods. 204 (1997) 77-87.
O'Brien, W.A., et al., HIV-1 tropism for Mononucleart Phagocytes can be determined by Regions of gp120 outside the CD-4 binding domain.
Olson, W.C., et al., “Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemoking Activity by Monoclonal Antibodies to CCR5,”Journal of Virology73 (1999) 4145-4155.
Oppermann, M., “Chemokine Receptor CCR5: Insights into Structure, Function and Regulation,”Cellular Signalling10 (2004) 1201-1210.
Orlandi, R., et al., “Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction,” Proc. National. Academic Science USA 86 (1989) 3833-3837.
Queen, C., et al., “A Humanized Antibody that binds to the Interleukin 2 Receptor,”Proc. National Academic Science USA86 (1989) 10029-10033.
Riechmann, L., et al., “Reshaping Human Anti-bodies for Therapy,”Nature332 (1988) 323-327
Schlaeger, E.J., et al., “Transient Gene Expression in Mammalian Cells grown in Serum-free Suspension Culture,”Cytotechnology30 (1999) 71-83.
Schlaeger, E.J., et al., “The Protein Hydrolysate, Primatone RL, is a cost effective Multiple Growth Promoter of Mammalian Cell Culture in Serum-containing and Serum-free Media and Displays Anti-apoptosis Properties,&#x
Brandt Michael
Sankuratri Surya
Schumacher Ralf
Seeber Stefan
Bristol Lynn A.
Green Grant D.
Roche Palo Alto LLC
LandOfFree
Antibodies against CCR5 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against CCR5 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against CCR5 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4125050